Virus cocktail takes on superbug pneumonia in ventilator patients
NCT ID NCT07202234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a cocktail of viruses called bacteriophages can treat ventilator-associated pneumonia caused by multidrug-resistant bacteria. 248 adults on ventilators will receive either the phage cocktail or a placebo via nebulizer. The goal is to see if the treatment improves infection clearance and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bacteriophage cocktail
- What this could lead to
- If it works, this could provide a new treatment option for hard-to-treat pneumonia caused by drug-resistant bacteria.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. The therapy may not improve outcomes or could cause side effects like allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VAP - VENTILATOR ASSOCIATED PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.